全文获取类型
收费全文 | 27664篇 |
免费 | 1717篇 |
国内免费 | 193篇 |
专业分类
耳鼻咽喉 | 132篇 |
儿科学 | 804篇 |
妇产科学 | 1075篇 |
基础医学 | 1684篇 |
口腔科学 | 414篇 |
临床医学 | 4163篇 |
内科学 | 4762篇 |
皮肤病学 | 236篇 |
神经病学 | 1725篇 |
特种医学 | 854篇 |
外科学 | 5325篇 |
综合类 | 1264篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 4119篇 |
眼科学 | 294篇 |
药学 | 1135篇 |
33篇 | |
中国医学 | 125篇 |
肿瘤学 | 1427篇 |
出版年
2024年 | 67篇 |
2023年 | 1858篇 |
2022年 | 2434篇 |
2021年 | 2473篇 |
2020年 | 2789篇 |
2019年 | 1498篇 |
2018年 | 1291篇 |
2017年 | 1309篇 |
2016年 | 1328篇 |
2015年 | 1240篇 |
2014年 | 2419篇 |
2013年 | 1709篇 |
2012年 | 1283篇 |
2011年 | 942篇 |
2010年 | 1332篇 |
2009年 | 1262篇 |
2008年 | 592篇 |
2007年 | 588篇 |
2006年 | 468篇 |
2005年 | 325篇 |
2004年 | 228篇 |
2003年 | 225篇 |
2002年 | 208篇 |
2001年 | 242篇 |
2000年 | 195篇 |
1999年 | 212篇 |
1998年 | 215篇 |
1997年 | 148篇 |
1996年 | 172篇 |
1995年 | 164篇 |
1994年 | 93篇 |
1993年 | 56篇 |
1992年 | 41篇 |
1991年 | 44篇 |
1990年 | 44篇 |
1989年 | 41篇 |
1988年 | 9篇 |
1987年 | 1篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1975年 | 3篇 |
1973年 | 1篇 |
排序方式: 共有10000条查询结果,搜索用时 359 毫秒
101.
102.
103.
《Journal of endodontics》2020,46(10):1371-1386.e8
IntroductionThis study aimed to summarize data on apical periodontitis (AP) and nonsurgical root canal treatment (NSRCT) prevalence and risk factors related to age, gender, and quality of restorative and endodontic treatment in the general population from cross-sectional studies published between 2012 and 2020.MethodsAn electronic search was performed in the following databases: Web of Science, Scopus, and PubMed. The conducted literature search covered studies published between 2012 and 2020, without restrictions on language. The STROBE and NOS tools were used for quality assessment of the included studies.ResultsSixteen articles were included in the review. In total, 200,041 teeth were examined. On average, 6.3% of teeth had AP, and 7.4% had NSRCT. Forty-one percent of RCT teeth had AP, and 3.5% of untreated teeth had AP. Female patients were less prone to AP in endodontically treated teeth only, compared with male patients (P < .001). Variable stratification of age subgroups among included studies prevented us from conducting a meta-analysis. An increase in AP frequency was found in teeth with inadequate restorative and endodontic treatment (P < .001 and P < .001, respectively). Because of high heterogeneity, these results should be taken with caution.ConclusionsThere is an increased AP prevalence in the adult general population compared with data from 2012 (6.3% versus 5.4%) in both endodontically treated (41.3% versus 35.9%) and untreated teeth (3.5% versus 2.1%). In addition, AP developed less frequently in female patients with endodontically treated teeth and in teeth with inadequate compared with adequate restorative and endodontic treatment. 相似文献
104.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2020,30(10):1732-1741
AimsTo explore the association between WWI and the incidence of HTN in the Rural Chinese Cohort Study.Methods and ResultsWe examined data for 10,338 non-hypertensive participants (39.49% men) aged ≥ 18 years from the Rural Chinese Cohort Study who completed a baseline examination during 2007–2008 and follow-up during 2013–2014. WWI was calculated as waist circumference (cm) divided by the square root of weight (kg). Multiple logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the probability of HTN across four WWI categories. Restricted cubic splines analysis was used to model the dose–response association of WWI and HTN. A total of 2078 participants had HTN during a median follow-up of 6 years. After adjusting for potential confounders, as compared with the lowest WWI category (<9.94 cm/√kg), with WWI 9.94 to 10.42, 10.42 to 10.91 and ≥ 10.91 cm/√kg, the ORs (95% CIs) for HTN were 1.12 (0.93–1.35), 1.40 (1.17–1.69) and 1.50 (1.24–1.82), respectively. Results of the sensitivity analyses were robust. The ORs were generally consistent on subgroup analysis by sex, smoking status, systolic blood pressure and diastolic blood pressure. Multiple logistic regression models with restricted cubic splines showed a non-linear positive association between WWI and HTN (Pnonlinearity < 0.001).ConclusionThe highest WWI category was significantly associated with increased risk of HTN. Our findings may facilitate the development and promotion of obesity prevention strategies aimed at reducing the risk of HTN and provide evidence for healthcare policy in rural China. 相似文献
105.
106.
107.
108.
109.
110.
《Clinical colorectal cancer》2020,19(4):285-290
BackgroundFOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC). Our aim was to investigate efficacy and tolerability of this combination in the first line.Patients and MethodsPatients with untreated documented mCRC received aflibercept plus FOLFIRI every 14 days until progression or unacceptable toxicity in an open, phase II single-arm, multicenter trial. The primary endpoint was the 6-month PFS rate. Secondary endpoints were OS and tolerability. A 2-step Simon design was used with H0: 55% and H1= 75%. Data were analyzed in intention to treat.ResultsForty-one patients were included, and 40 were analyzed (1 consent withdrawal) in 9 French centers between October 2014 and February 2017. The median age was 65 years (range, 46-81 years), 55% had ≥ 2 metastatic sites, and 50% and 15% had RAS and BRAF mutations, respectively. Twenty-two (54.5%; 95% confidence interval, 38.9%-68.5%) patients were alive and non-progressive at 6 months. FOLFIRI + aflibercept was considered ineffective, resulting in the cessation of inclusions. The median follow-up was 34 months. The overall response rate was 55%, and the disease control rate was 80%. The median duration of treatment was 5.3 months; the median PFS and OS were 8.2 and 18.6 months, respectively. Grade 3 to 4 adverse events were mainly gastrointestinal (47.5%) and vascular (32.5%). Of the patients, 87.5% had at least 1 dose modification.ConclusionAlthough the primary objective was not met, first-line FOLFIRI + aflibercept for mCRC leads to median PFS and OS close to those reported with classical doublet and targeted agents, but with significant toxicities needing dose reduction. 相似文献